Celebrex Data Requested By FDA May Clarify Cancer Risk Reduction Potential
FDA is requesting data from a Searle Phase III trial that could elucidate the cancer risk reduction that Celebrex provides for patients with familial adenomatous polyposis.
FDA is requesting data from a Searle Phase III trial that could elucidate the cancer risk reduction that Celebrex provides for patients with familial adenomatous polyposis.